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Calcification is a frequent cause of the clinical failure of bioprosthetic heart valves fabricated from 
glutaraldehyde-pretreated porcine aortic valves or glutaraldehyde-pretreated bovine pericardium 
(GPBP). We investigated the hypothesis that ferric chloride (FeCI,) and sodium- 
ethanehydroxydiphosphonate (EHDP) may act synergistically to prevent bioprosthetic tissue 
calcification. Pre-incubations and controlled release systems were studied individually. FeC13- 
EHDP polymeric controlled release matrices were formulated using silicone rubber and 
evaluated for in vitro release kinetics at pH 7.4 and 37°C. The effects of Fe-EHDP synergism on 
GPBP calcification were investigated with 21 d subdermal implants in 3 wk-old male rats. Results 
demonstrated that levels of Fe3+ and EHDP uptake, measured in GPBP tissues pre-incubated 
first in an FeCI, solution (10e5 M) followed by an EHDP solution (0.1 M), were higher than in the 
reverse order of incubation. In the first series of rat implants, GPBP was pre-incubated in either 
FeCI, or Na,EHDP solutions, or sequential pre-incubations of first FeCI, and then Na,EHDP 
solutions, or the reverse. The inhibition of calcification was greatest when FeC13 (first pre- 
incubation, 10e5 M) was combined with Na*EHDP (second pre-incubation, 0.1 M) (1.78 f 0.2pg of 
Ca*+/mg of dried tissue) compared with the other pre-incubation groups: EHDP (first pre- 
incubation) combined with FeCI, (second pre-incubation) (21.7 k 6.4) FeCI, solution alone at 
10m5 M (27.9 + 10.7), Na2EHDP solution alone at 0.1 M (52.3 + 11.9) and the control group 
(72.3 + 10.2). In a second series of implants, G.PBP specimens were co-implanted with individual 
controlled release systems containing one of the following formulations (weight percentage in 
silicone rubber): 1% FeCI,, 20% CaEHDP, 20% protamine sulphate, 1% FeCI,-20% CaEHDP, and 
1% FeCI,-20% protamine sulphate. The 1% FeC13-20% CaEHDP silicone-rubber matrices were 
the most effective for inhibiting GPBP mineralization (13.7 t 3.0,ag Ca*+/mg of dried tissue) 
compared with non-drug silicone co-implant controls (74.7 f 5.56 pg Ca*+/mg of dried tissue) 
and other polymeric treatment groups (32.3 + 2.3-80.0 Ifr 19.7). No adverse effects on bone or 
overall growth of any treatment protocols were noted. Thus, combinations of FeC13 and EHDP, 
using either pre-incubations or polymeric controlled release, were synergistic for inhibiting 
GPBP calcification. 
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valves or bovine pericardium (GPBP) is a frequent cause 
of clinical failure’. Investigations of the initial calcific 
foci in bioprosthetic calcification have shown’. 3 that the 
first mineral deposits are localized within glutaraldehyde- 
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devitalized cells, and within various organelle membrane 
sites3. Collagen calcification occurs later in the develop- 
ment of experimental subdermal GPBP calcification4. 
There is no completely successful strategy for preventing 
the intrinsic deposition of calcium phosphates within 
these cardiovascular implants. 
Various anticalcification agents, including metallic 
salts’, 5, detergents6 and diphosphonates7-g have been 
used in a variety of therapeutic schemes including 
systemic administrations, pre-incubations or co-implanted 
polymeric controlled release drug delivery systems. 
Regional controlled release of anticalcification drugs 
from drug-polymer composites (known as controlled 
release matrices) has been demonstrated experimentally 
to inhibit bioprosthetic calcification. This approach 
allows local site-specific administration of the drug, 
thus minimizing dose requirements, while avoiding the 
possible development of systemic adverse effects. 
In previous studies, GPBP pre-incubated in dilute 
aqueous solutions of either AlCl, or FeCl,, did not 
develop pathological mineralization when implanted 
subdermally in rats ‘3 5, The mechanism of Fe3+ or A13+ 
inhibition of GPBP calcification is incompletely under- 
stood, but may be due to inhibition of calcium phosphate 
crystallization or a reduction in alkaline phosphatase 
(AP) activity, or both. AP is an enzyme of recognized 
importance in physiological calcification of bone’, and is 
present in GPBP calcification. Its activity is also 
inhibited by GPBP pretreatment with AlCl, or FeCl, in rat 
subdermal implant studies3. Similarly, co-implanted 
controlled release polymeric matrices containing AlCl, 
and FeCl, also inhibit GPBP calcification in other rat 
subdermal studies7. However, the mechanism of action 
of these agents may also be related to their interactions 
with phosphorus loci within membranes of devitalized 
cells’ and other phosphorus-rich organelles present in 
GPBP; these sites are thought to be the initial sites of 
calcium phosphate formation49 lo. 
Another group of agents, the diphosphonates, has 
been investigated for use in the prevention of GPBP 
calcificatior?. The diphosphonates, pyrophosphate 
analogues, can bind to developing calcium phosphate 
crystals, and may effect calcification inhibition due 
to crystal poisoning effects”, with resultant limiting 
of crystal growth. Pre-incubation studies of covalent 
binding of aminopropanehydroxydiphosphonate (ADPD) 
to residual aldehyde groups, resulting from glutaraldehyde 
fixation of GPBP, markedly inhibited calcification of 
GPBP in rat subdermal implants’; however the progressive 
leaching of ADPD from GPBP implants probably 
explains the lack of inhibition of calcification in long- 
term sheep circulatory implants”. In related research, 
sodium ethanehydroxydiphosphonate (Na,EHDP) con- 
trolled release matrices were co-implanted subdermally 
with GPBP tissue, and also inhibited calcification’3. 
However, this same drug used in pre-incubation studies 
with GPBP did not prevent the mineralization in rat 
subdermal implants14; this lack of efficacy was most 
likely due to a diffusion of EHDP out of GPBP tissue. 
The goals of the present study were to assess the 
possible synergistic effect of diphosphonates and metallic 
salts on inhibiting bioprosthetic tissue mineralization. 
Therefore, the effects of FeCl, combined with EHDP (either 
by successive GPBP pre-incubations or co-incorporation 
in silicone-rubber matrices) were investigated on GPBP 
calcification in rat subdermal implant experiments. 
MATERIALS AND METHODS 
Materials 
Ferric chloride (reagent grade) and potassium phosphate 
were purchased from Fisher (Fairlawn, NJ, USA). 
Protamine sulphate (PS), N-2-hydroxyethylpiperazine- 
N’-2-ethanesulphonic acid (HEPES) and calcium chloride 
were obtained from Sigma (St Louis, MO, USA). Non- 
radiolabelled and radiolabelled sodium ethanehydroxy- 
diphosphonate (Na,[‘4C] EHDP, specific activity of 
48.9&i/mmol) were donated by Procter and Gamble 
(Cincinnati, OH, USA). The scintillation fluid, Ecolume, 
was purchased from ICN Biomedicals (Irvine, CA, USA). 
A polydimethylsiloxane Silastic Q-74840 was obtained 
from Dow Corning (Midland, MI, USA). Ketamine 
hydrochloride (Aveco, Fort Dodge, IA, USA] and 
Rompun@ (Haver, Shawnee, KS, USA] were used for 
anaesthesia. 
Pericardium from mature bovines was obtained fresh 
at slaughter, and was cross-linked as previously 
described4’ lo in a 0.8% glutaraldehyde (diluted from an 
8% aqueous solution, Polyscience, Warrington, PA, USA) 
solution buffered with 50 mM HEPES at pH 7.4, then 
transferred after 24 h to a 0.2% glutaraldehyde solution 
in the same buffer for storage at 4°C for 1 wk. 
Methods 
In vitro pre-incubations 
GPBP specimens (1 cm’) were rinsed free of glutaraldehyde 
with sterile saline and successively pre-incubated at 
37°C in the FeCl, solution (1O-5 M, pH 3 for 24 h), then in 
the Na214C-EH.DP (0.1 M, pH 7.4 for 24 h), or vice versa. 
Control specimens of GPBP were pre-incubated in 50 mM 
HEPES buffer, pH 7.4 for 24 h at 37%. Afterward, the 
samples of pre-incubated GPBP were withdrawn, washed 
with distilled water and lyophilized. Half of the specimens 
were dissolved in tissue solubilizer (Solvable, DuPont, 
Boston, MA, USA) at 55-60°C and the Na,14C-EHDP 
was measured. The other specimens were minced, 
hydrolysed in 6 N HCl as previously described4’ lo, and 
the Fe3+ levels were determined by atomic absorption 
spectroscopy15. 
Controlled release polymer formulation and in vitro 
release studies 
All the agents (wt%/matrix) were incorporated as a 
matrix dispersion in Silastic Q-74840 prepolymer. The 
silicone-rubber formulations containing the cocipients 
were prepared by levigating the A and B components of 
Silastic Q-74840 thoroughly with the drug, followed by 
compression moulding and curing at 250°C for l-2 h 
using a hydraulic press (70.2 X lo5 Pa). 
The in vitro release of agents from slab materials 
(1 cm’] was conducted at 37°C using either an excess 
of 50 mM HEPES buffer pH 7.4 or K,HPO, buffer (pH 
7.4). At each time point, 1 ml samples were withdrawn 
and the drug release was estimated. The Fe3+ content was 
measured chemically by atomic absorption spectroscopy’5. 
The Na,EHDP content was determined by measuring the 
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released radioactivity of NaZf4C-EHDP with a liquid 
scintillation counter (Model LS 3801, Beckman, USA), 
and the PS release was analysed by using Lowry protein 
assayX6. 
Implant and retrieval methods 
Male weanling rats (50-60 g, CD, Sprague-Dawley, 
Charles River Laboratories, Burlington, MA, USA) were 
anaesthetized by an intramuscular injection of Ketamine 
and Rompun. Six subdermal pouches were dissected as 
previously described4* *’ on each rat (four ventral, two 
dorsal) and GPBP specimens (1 cm’), washed with 
distilled water to remove residual glutaraldehyde, were 
implanted in these pouches, either as isolated GPBP 
implants or as co-implants with polymeric matrices 
(1 cm’, approximately 100 mg), with or without drugs, 
linked by surgical staples. The rats (two per group) were 
killed by CO, asphyxiation after 21 d. Explanted GPBP 
were washed with saline and distilled water, lyophilized 
and hydrolysed in 6 N HCl, as previously described, for 
calcium analysis by atomic absorption spectroscopy4, lo. 
Morphological analysis 
Representative samples of each explanted group were 
immediately fixed in 2.5% glutaraldehyde, 2% paraform- 
aldehyde and cacodylate buffer, pH 7.4 (Karnovsky’s 
fixative) . I7 Representative specimens of femurs were 
fixed in 10% neutral buffered formalin. The specimens of 
valves and bones were dehydrated in graded ethanol 
solutions and embedded in JB-4 glycolmethylmethacrylate 
medium (Polysciences, Warrington, PA, USA). Sections 
2-3 pm thick were stained with haematoxylin and eosin 
(for overall morphology) and Von Kossa’s reagent (for 
calcium phosphate), 
RESULTS 
Maximum uptake of Fe3+ and EHDP, and Fe3+ 
dissociation from GPBP tissues 
The results presented in ‘Rbk f demonstrate that the 
sequence of pre-incubation had a significant effect on the 
Fe3+ and Na,EHDP content of the GPBP tissues. Initial 
pre-incubations of GPBP tissues in the FeCl, solution, 
followed by the Na,EHDP solution, resulted in Na,EHDP 
uptake an order of magnitude greater than the reverse 
sequence of pre-incubation. 
The Fe3+ release from the successive pre-incubations 
by GPBP tissues are shown in Figure 1. Both conditions 
studied demonstrated their most rapid elution rates 
during the first 24 h. After this time, a slower nearly 
constant release rate of Fe3 was noted to be roughly 
equal in both types of specimens. The Fe3” release rate 
from the GPBP tissues pre-incubated initially in the FeC& 
solution, then in the Na,EHDP solution, was almost twice 
as rapid during the first 24 h as for the GPBP tissues pre- 
incubated in the reverse order. 
In vitro releases of EHDP and Fe3+ from the 
polymeric matrices 
The results of in vitro release studies of the polymeric 
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Figure1 Fe3+ release profiles as cumulative percentage 
from pre-incubated GPBP tissues in vitro. Each symbol 
represents the mean of three specimens. 0, FeCI, (1O-5 An/first 
pre-incubation)/Na*EHDP (0.1 M/second pre-incubation); 0, 
Na,EHDP (0.1 M/first pre-incubation)iFeCI, (low5 M/second 
pre-incubation). 








Control 72.3 + 10.2 
10m5 M FeCI, 
(10) 
9.1 M EHDP 2.5 f 1.0 (5f 184.3 + 14.700 1.8 i 0.2’ 
lo-’ M FeCl, 
(5) (10) 
0.1 M EHDP 2.1 f 1.1 (5) 18.7 A 21.7 f 6.4’ 
1 Om5 M FeCI, 
1.100 (5) (10) 
1.3 f 0.2 (5) 27.9 f 10.7 (10) 
0.1 M EHDP 0.1 f 0.006 (5) 52.3 t 11.9 (10) 
Mean + SEM (n). 
‘nM/mg dried tissue. 
“pg/mg dried tissue. 
+P < 0.0006 compared with control. 
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Figure 2 Fe3’ release profiles as cumulative percentage from 
q , 1% FeCI,-20% CaEHDP and 0, 1% FeCI,-20% protamine 
sulphate (PS) matrices (Silastic rubber polymer) during 21 d. 
depicted in Figure 2. Relatively slow sustained release of 
Fe3+ was noted with both types of matrices. After 21 d, 
the Fe3+ release from the polymeric matrix containing 
1% FeCl,-20% CaEHDP (5%) was almost three times that 
of the 1% FeCl,-20% PS (2%). 
In tivo studies 
The calcium levels of 21 d subdermal implantations of 
GPBP tissues pre-incubated in either FeCl, or Na,EHDP 
solutions, or FeCl, combined with Na,EHDP are presented 
in ZWe 3. Pre-incubation in Na,EHDP (0.1 M) did 
not significantly inhibit the calcification (52.3 f 11.9 ,ug 
Ca’+/mg dried tissue) while FeCl, (lo-’ M) pre-incubation 
partially inhibited the calcium accumulation (27.9 + 
10.7 pg Ca’+/mg dried tissue] compared with the control 
group (72.3 + 10.2 pg Ca’+/mg dried tissue]. The greatest 
inhibition ,was observed when the GPBP tissue was first 
pre-incubated in FeCl, (lo-’ M for 24 h) and then in 
Na,EHDP (0.1 M for another 24 h) (1.8 + 0.2 ,ug Ca’+/mg 
dried tissue). The reverse order of pre-incubation inhibited 
calcification less effectively than the previous group 
(21.7 I!Z 6.4j.ig Ca’+/mg dried tissue). The later calcium 
level was similar to the FeCl,-only pre-incubation group 
(7Me 1). 
Co-implantation results of the FeCl,-CaEHDP con- 
trolled release systems with GPBP tissues are presented 
in Figure 3. The extensive calcification of the 
GPBP tissue co-implanted with matrices containing only 
low-level loadings of FeCl, or CaEHDP or protamine 
was comparable with that of the control group, where 
a non-drug polymer co-implant was used (range of 
Ca2+ = 58.1 f 10.2-74.7 + 5.6 pg/mg). The matrices 
containing 1% FeCl,, with either 20% CaEHDP or 20% 
PS in the polymer co-implant studies, demonstrated that 
Control l%Fe 2l%EHDP ZO%PS FelPS FelEHDP 
Matrix cocipient 
Figure 3 Calcium levels from GPBP tissue explants after co- 
implantation with various drug-polymer matrices (1% FeCI,, 21% 
CaEHDP, 20% protamine sulphate (PS), 1% FeCI,-20% 
protamine sulphate (Fe/PS), 1% FeCI,-20% CaEHDP (Fe/EHDP)) 
from rat subdermal implants (21 d). Data are shown as means 
with standard error bars. 
the co-drug CaEHDP plus FeCl, was significantly more 
efficient in calcification inhibition (13.7 f 3 ,ug Ca’+/mg) 
than the PS (32.3 f 2.3flg Ca’+/mg) or the control 
polymer (non-drug] group (74.7 f 5.6pg Ca’+/mg). 
Additionally, rat growth was not significantly impaired 
by either the pretreatments or the silicone-rubber co- 
implants (weight gain range 95.9-99.1% of control). The 
morphology of the explanted tissues corroborated the 
chemical analysis. Tissue co-implanted with the polymer 
containing CaEHDP plus FeCl, had markedly less 
calcification than that of tissue in the control polymer 
group (Figure 41. Stains of this tissue for iron revealed 
moderate staining for iron in some specimens, localized 
to intrinsic pericardial cells (result not shown]. 
DISCUSSION 
The present study demonstrated that FeCl, and EHDP 
acted synergistically to inhibit bioprosthetic tissue 
calcification in the rat subdermal model (21 d), whether 
administered by GPBP pre-incubation or controlled 
release co-implants. The prevention of GPBP calcification 
was significantly reduced in both types of inhibition 
studies: pre-incubations of GPBP tissues in successive 
FeCl, (lo-’ M) and then Na,EHDP (0.1 M) solutions: and 
the FeCl, (l%)-CaEHDP (20%) controlled release system. 
The FeCl,-Na,EHDP pre-incubation synergism results 
point out the importance of the pre-incubation sequence. 
The optimal incubation order, FeCl, followed by Na,EHDP, 
allowed a higher uptake of both drugs, FeCl, and 
Na,EHDP, into the GPBP tissue. The reasons for the 
importance of the sequence of pre-incubation are not 
clear. Diphosphonates and water molecules may have 
formed complexes, as previously described”, and there- 
fore the Fe3+ ions are probably less easily incorporated 
into the tissue in the presence of these complexes. 
Alternatively, Fe3+ may form complex precipitates with 
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a 
Figure4 Markedly diminished calcification of tissue co- 
implanted with polymer containing CaEHDP plus FeCI, relative 
to control tissue. Tissues were implanted for 21 d sub- 
cutaneously in young rats. a, Tissue adjacent to polymeric 
implant; b, control tissue. Von Kossa stain (calcium phosphates 
black) (original magnification X150). 
GPBP phosphates, which then readily adsorb EHDP, 
due to ionic attraction. Prior work by our group has in fact 
used electron energy-loss spectroscopy to demonstrate 
colocalization of A13+ (as an AlCl, pre-incubation) to 
GPBP phosphorus sites in cell membranes. Initial 
incubation with EHDP may block the metal-phosphorus 
interaction, leading to lower metal ion and EHDP 
uptake. 
Controlled release of Na,EHDP has been demonstrated 
to be effective for inhibiting calcification in the rat 
subdermal modeV3, lg. “, while the GPBP pre-incubation 
in Na,EHDP did not inhibit calcification’4. Our data 
(Figure 3) show that 21% CaEHDP alone loaded into 
silicone-rubber matrices did not significantly inhibit 
GPBP mineralization compared with the control. The 
calcium salt of EHDP is 1000 times less soluble than the 
sodium salt14, so less drug will be released from CaEHDP 
matrices. Furthermore, other related work involving co- 
implantation of Fe3+ (10% loaded) or A13+ (1 or 10% 
loaded) controlled release systems with GPBP tissue in 
the rat subdermal implants (21 d) demonstrated anticalci- 
fication efficacy7. In this study, Fe3+ was loaded at a 
lower percentage (1%) than the previous studies just 
cited, so the Fe3+ release profile (Figure 2) also showed 
significantly slower release rates compared with earlier 
results7. Nevertheless, efficacy was evidently due to 
EHDP synergism. 
PS is an inhibitor of GPBP calcification, but only when 
covalently bound to the tissue”; its mechanism is 
hypothesized to be due to charge modification. A 
previous paper by our group also reported the failure of 
controlled release PS for calcification inhibition using 
10% loading PS in Q-74840 matrices7. Therefore, the 
controlled release PS used in the present study may be 
viewed as a control cocipient, since our earlier results 
demonstrated no effective inhibition of GPBP calcification 
using PS controlled release matrix co-implants. 
Pre-incubations of bioprosthetic tissue in trivalent 
metallic salts such as FeCl, or AlCl, prevented GPBP 
implant calcification’* ’ in rat subdermal studies. At the 
same time, explant AP activity was reduced due to FeCl, 
or AlCl, pre-incubation during the first 72 h following 
implantation compared with the contro13. In the rat 
subdermal model of GPBP calcification, AP activity 
normally has a peak activity at 72 h, at which time 
calcium phosphate accumulation is initiated. Morpho- 
logical studies showed that A13+ and Fe3+ are localized on 
the GPBP devitalized cells’, which are the loci of the 
initial calcific deposits. Comparable results from bone 
research studies showed that matrix vesicle mineral- 
ization, also associated with AP, was inhibited by metal 
ions”. Matrix vesicles, membrane-enclosed structures, 
are known to be involved in the initiation of calcification 
in both endochondral bone and pathological mineral- 
ization23-25, including dystrophic calcifications occurring 
in atherosclerosis and stenotic native aortic valve!?. 
Previous work from our laboratory has demonstrated 
that the first mineral deposits in the bioprosthetic heart 
valve subdermal model were most often localized on 
devitalized cell and organellar membrane locations’. 
Electron energy-loss spectroscopy studies have demon- 
strated that those organelles are rich in phosphorus’. 
Therefore the presence of the metallic ions and phosphorus 
at the same site in the tissue suggests that metallic salts 
may act by inhibiting the initiation of calcification, since 
phosphorus-containing compounds, such as acidic phos- 
pholipid complexes, have been shown to be involved as 
mineralization initiators in bone and dystrophic calcifi- 
cation27-2g. Others studies have shown that both A13+ and 
Fe3+ ions inhibit hydroxyapatite formation and dissolu- 
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tion in vitro30131. EHDP synergism must build on this 
already known phenomenon of Fe3+ inhibition, by 
formation of additional complexes resistant to calcifi- 
cation. 
Dystrophic calcification is a multifactorial process, 
and therefore the best therapeutic strategy may be to seek 
drug action at different stages of the calcium phosphate 
deposition. Since the metallic salts are probably involved 
in suppressing the calcification initiation, and the 
diphosphonates probably act in the progression stage of 
mineralization processes, the combination of these two 
drugs resulted in a synergistic prevention of GPBP 
calcification. The incorporation of these two types of 
anticalcification agents in the GPBP tissue by pretreatment 
or controlled release polymeric matrices may offer a new 
viable solution to the clinical problem of dystrophic 
calcification. The controlled release system has the 
advantage of avoiding adverse systemic side-effects’,“, 
and enhancing local drug concentrations. Further studies 
combining other drugs may help the understanding of the 
pathological calcification in bioprosthetic heart valves. 
ACKNOWLEDGEMENTS 
The work was supported in part by National Institutes of 
Health (NIH) grant HL 38118. We also thank Mrs 
Catherine Wongstrom for her assistance in preparing the 
manuscript. 
REFERENCES 
Schoen, F.J., Levy, R.J. and Piehler, H.R., Pathological 
considerations in replacement cardiac valves, Cadiovasc. 
Pathol. 1992,1, 29-52 
Webb, CL., Schoen, F.J., Flowers, W.E., Alfrey, AC., 
Horton, C. and Levy, R.J., Inhibition of mineralization of 
glutaraldehyde-pretreated bovine pericardium by AlCI,. 
Mechanisms and comparisons with FeCI,. LaCl, and 
Ca(NO,), in rat subdermal model studies, Am. J. Pathol. 
1991, 138, 971-981 
Levy, R.J., Schoen, F.J., Flowers, W.B. and Staelin, S.T., 
Initiation of mineralization in bioprosthetic heart valves: 
studies of alkaline phosphatase activity and its inhibition 
by AlCl, or FeCI, preincubation, I. Biomed. Mater. Res. 
1991,25,905-935 
Schoen, F.J., Levy, R.J., Nelson, AC., Bernhard, W.F.. 
Nashef, A. and Hawley, M., Onset and progression of 
experimental biopmsthetic heart valve calcification, 
Lab. Invest. 1965, 52, 523-532 
Webb, C.L., Flowers, W.E.. Boyd, J., Rosenthal, E.L., 
Schoen, F.J. and Levy, R.J., A13’ binding studies and 
metallic cation effects on biopmsthetic heart valve 
calcification in the rat subdermal model, Trans. Am. Sot. 
Artif. Intern. Organs 1990, 38, 56-59 
Jones, M.. Eidbo, E.E., Hilbert, S.L., Ferrans. V.J. and 
Clark, R.E., Anticalcification treatments of bioprosthetic 
heart valves: in vivo studies in sheep, I. Cardiac Surg. 
1969, 4, 69-73 
Pathak, Y.V.. Boyd, J., Levy, R.J. and Schoen, F.J., 
Prevention of calcification of glutaraldehyde pretreated 
bovine pericardium through controlled release polymeric 
implants: studies of Fe3+, Ala+, pmtamine sulphate and 
levamisole, Biomaterials 1990, 11, 716-723 
Levy, R.J., Hawley, M.A., Schoen, F.J., Lund, S.A. and 
Liu, P.Y., Inhibition by diphosphonate compounds of 
calcification of porcine biopmsthetic heart valve cusps 
















Webb, C.L., Schoen, F.J. and Levy, R. J., Covalent binding 
of aminopmpanehydmxydiphosphonate to glutaraldehyde 
residues in pericardial biopmsthetic tissue: stability and 
calcification inhibition studies, Exp. Mol. Pathol. 1969, 
50, 291-302 
Schoen, F.J., Tsao, J.W. and Levy, R.J., Calcification of 
bovine pericardium used in cardiac valve biopmstheses. 
Implications for the mechanisms of bioprosthetic tissue 
mineralization, Am. J. Pathol. 1986, 123, 134-145 
Fleisch, H., Bisphosphonates: a new class of drugs in 
diseases of bone and calcium metabolism, Recent Results 
Cancer Res. 1969.18, l-28 
Jones, M., Eidbo, E.E., Hilbert, S.L., Ferrans, V.J. and 
Clark, R.E., The effects of anticalcification treatments on 
biopmsthetic heart valves implanted in sheep, ASAIO 
Trans. 1968, 34,1027-1030 
Golomb, G., Langer, R., Schoen, F.J., Smith, M.S., Choi, 
Y.M. and Levy, R.J., Controlled release of diphosphonate 
to inhibit biopmsthetic heart valve calcification: dose- 
response and mechanistic studies,l. ControlledRel. 1986, 
4.181-194 
Johnston, T.P., Schoen, F.J. and Levy, R.J., Prevention of 
calcification of bioprosthetic heart valve leaflets by 
calcium diphosphonate pretreatment,]. Pharm. Sci. 1988, 
77, 740-744 
Van Loon, J.C., Analysis of samples, in Analytical 
Atomic Absorption Spectroscopy Academic Press, NY, 
USA 1980, p 168 
Lowry, O.H., Rosebrough, N.O.and Farr, A.L., Protein 
measurement with the Folin phenol reagent, I. Biol. 
Cbem. 1951, lB3,265-275 
Karnovsky, M.J., A formaldehyde-glutaraldehyde fixative 
of high osmolality for use in electron microscopy, 1. Cell 
Biol. 1965, 27, 137A-136A 
Lamson, M.L., Fox, J.L. and Higuchi, WI., Calcium and 
l-hydmxyethylidene-l,l-bisphosphonic acid: polynuclear 
complex formation in the physiological range of pH, ht. 
J. Pharm. 1884, 21,143-154 
Levy, R.J., Wolfrum, J., Schoen, F.J., Hawley, M.A., 
Lund, S. and Langer, R., Inhibition of calcification of 
biopmsthetic heart valve calcification by local controlled 
release of diphosphonate, Science 1985, 228, 190-192 
Golomb, G., Dixon, M., Smith, M.S., Schoen, F.J. and 
Levy, R.J., Inhibition of bioprosthetic heart valve calci- 
fication by sustained local delivery of Ca and Na 
diphosphonate via controlled release matrices, J. Trans. 
Am. Sot. Artif. Intern. Organs 1988, 32, 587-590 
Golomb, G. and Levy, R.J.. Prevention of calcification of 
glutaraldehyde-treated biomaterials by charge modifi- 
cation. Trans. Sot. Biomater. 1987, 10, 179 
Sauer, G.R., Adkisson, H.D., Genge, B.R. and Wuthier, 
R.E., Regulatory effect of endogenous zinc and inhibitory 
action of toxic metal ions on Ca accumulation by matrix 
vesicles in vitro, Bone Miner. 1989. 7, 233-244 
Anderson, H.C., Vesicles associated with calcification in 




Wuthier, R.E., A review of primary mechanism of 
endochondral calcification with special emphasis on the 
mle of cells, mitochondria, and matrix vesicles, Ch. 
Orthop. 1982, 189, 219-242 
Wuthier, R.E., Mechanism of matrix vesicle-mediated 
mineralization of cartilage, ISIAtlas Sci.: Biocbem. 1988, 
231-241 
26 Kim, K.M., Valigorsky, J.M., Mergnere, W.J., Jones, R.T., 
Pendergrass, R.F. and Trump, B.F., Aging changes in the 
human aortic valve in relation to dystrophic calcification, 
Hum. Pathol. 1976, 7, 47-60 
27 Boskey, A.L. and Posner, A.S., Extraction of a Ca- 
implanted subcutaneously in rats, Circulation 1985, 71, 
349-356 
Inhibition of bovine pericardium calcification: D. Hirsch et al. 
phospholipid-phosphate complex from bone, Calcif. 
Tissue Res. 1976,18,273-283 
28 Boskey, A.L. and Posner, AS., The role of synthetic 
and bone extracted Ca-phospholipid-PO, complexes in 
hydroxyapatite formation, Calcif. Tissue Res. 1977, 23, 
251-258 
29 Kim, K.M., Lipid matrix of dystrophic calcification and 
urinary stone, SEM 1983,1275-1284 
711 
and amorphous calcium phosphate as a model for 
aluminum associated osteomalacia, in The Chemistry 
and 3i~i~g~ of MiRera~jzed Tissues (Ed. W.T. ButtlerJ, 
Ebsco Press, Birmingham, AL, USA, 1985, p 385 
31 Christoffersen, M.R. and Christoffersen, J., The effect of 
aluminum on the rate of dissolution of calcium hydroxy- 
apatite-a contribution to the understanding of aluminum- 
induced bone diseases, Caicif. Tissue ht. 1985, 37, 
30 Blumenthal, NC, Binding of aluminum hydroxyapatite 673-676 
European Society for Biomaterials 
10th European Conference 
on Biomaterials 
Davos, Switzerland S-11 September 1993 
The Conference will consist of keynote lectures delivered by invited speakers, thematically 
selected oral presentations, and lectures from ESB-Award winners. The oral component of the 
conference will be accompanied by poster presentations, including “last minute“ contributions 
(deadline - end of July). Time has been allotted for the discussion of specific topics. 
0 Conference topics 
0 Systemic effects due 0 Interactions between polymers 
to implants and cells/tissues 
* Biodegradable materials 0 Polymer-protein interactions 
0 Interface mechanics I, Bioactive polymers 
0 Interface biology l Composites & hybrid materials 
The scientific program will be supplemented by workshop discussions with a limited number 
of participants. 
0 Workshop themes 
a Clinical evaluation of biomaterials. Coordinator: J. Cordey 
0 New trends in internal fixation of fractures. Coordinator: S.M.Perren 
0 Biodegradable implant materials. Coordinator: S. Gogolewski 
0 High resolution techniques in biomaterial evaluation. Coordinators: S. Downes & 
H.K. Koerten 
For further details please contact: Dr B.A. Rahn, 10th ESB-Meeting, AO-Research Institute, 
Clavndelerstrasse, CH-7270 Davos, Switzerland. Fax: 41 81 442 288. 
Biomaterials 1993, Vol. 14 No. 9 
